RxDoctor Payments Data

Robert Luangkhot, MD

Urology · Flushing, NYNPI 1164485421

Payments from drug & device makers

$11,629in general payments, 2019–2025

Across 141 payments — averaging $82.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$4K
  • Astellas Pharma US Inc$4K
  • Johnson & Johnson$2K
  • Pfizer$316
  • Bayer$288
  • Sumitomo Pharma America, Inc.$270
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1001%
  • Speaking & faculty fees$4,35037%
  • Travel & lodging$1,53813%
  • Food & beverage$4,87442%
  • Education$7677%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,629 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$151,042
Medicare patients
352
Services billed
2,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate32$379,279
XtandiEnzalutamide19$326,965
GemtesaVibegron313$300,575
MyrbetriqMirabegron203$157,176
OrgovyxRelugolix45$122,485
Tamsulosin Hcl2,314$30,757
Potassium Citrate ErPotassium Citrate135$21,390
Finasteride1,730$14,806
Tadalafil44$7,043
CialisTadalafil15$6,701
Estradiol65$6,091
Desmopressin Acetate38$5,163
Silodosin38$3,849
Oxybutynin Chloride ErOxybutynin Chloride228$3,739
RapafloSilodosin12$3,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$3,727$484,141222 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$270$423,060358 claims
AbbVieLupron Depot$39$379,27932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →